Please login to the form below

Not currently logged in

Daily Brief: Resignation throws Brexit into disarray, Celgene exec joins Orchard board, Scotland rules on EUSA drug

News from pharma, biotech and healthcare

Minister’s resignation throws Brexit plan into disarray

Theresa May has seen her plans for Brexit dealt a huge blow by the resignation of David Davis, the minister in charge of leading the process.

David Davis

Davis tendered his resignation early this morning, after the prime minister had declared a consensus had been reached on Friday among her cabinet of ministers, who have long been divided into former 'Remain' and Brexiteer camps.

Despite the apparent cabinet agreement reached on Friday, Davis has now indicated that the plan is far too ‘soft’ a Brexit for him, saying that the UK will be permanently tied to EU regulations, and won’t be able to break away as planned.

Davis said Theresa May had "given away too much too easily".

A muted reaction from the markets suggest that investors believe the UK is still heading for a soft Brexit – although many businesses are far from convinced that the UK government current proposal on trade and customs is sufficiently ‘frictionless’ or indeed one that will ever be accepted by the EU27.

Housing minister and Brexiteer Dominic Raab has been named as Davis’ successor.

Read more at the Guardian here

Celgene’s Beck joins Orchard Therapeutics board

Promising UK cell and gene therapy company Orchard Therapeutics has bolstered its board with an experienced pharma drug development and supply chain expert, Celgene’s Dr Joanne Beck (pictured).

Joanne Beck

Dr. Beck is executive vice president of pharmaceutical development and operations and a member of the executive committee at Celgene.

Mark Rothera, president and CEO of Orchard said, “We are thrilled to have Joanne join our board. Her extensive experience in pharmaceutical development, global manufacturing operations and quality will serve our company very well as we accelerate our plans to implement a global supply chain of transformative gene therapies.”

Prior to Celgene, Dr. Beck was senior vice president of pharmaceutical development at Shire from 2012 to 2016.

Dr. Beck commented: “I am pleased to be joining Orchard’s board of directors at such a pivotal time in the company’s development. I look forward to working with the board and leadership team as Orchard implements a global supply chain that delivers personalised gene therapies to patients.”

EUSA’s Fotivda approved for NHS use in Scotland

Specialist pharma company EUSA Pharma has welcomed the Scottish Medicines Consortium approval of its renal cell carcinoma treatment Fotivda (tivozanib).

The SMC has approved its use on the NHS as a first-line treatment for people with advanced renal cell carcinoma (RCC), which could enable around 165 eligible patients in a year to access this treatment through the NHS in Scotland.

9th July 2018

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...